Alphabetical Sort


tisagenlecleucel (01-17-2018)

Generic Name: tisagenlecleucel Trade Name: KYMRIAH For which conditions is this drug approved? KYMRIAH is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second... Continue Reading

KYMRIAH™ (01-17-2018)

Generic Name: tisagenlecleucel Trade Name: KYMRIAH For which conditions is this drug approved? KYMRIAH is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second... Continue Reading

YESCARTA™ (01-17-2018)

Generic Name: axicabtagene ciloleucel Trade Name: YESCARTA For which conditions is this drug approved? YESCARTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphomas after two or more lines of systemic treatment.... Continue Reading

axicabtagene ciloleucel (01-17-2018)

Generic Name: axicabtagene ciloleucel Trade Name: YESCARTA For which conditions is this drug approved? YESCARTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphomas after two or more lines of systemic treatment.... Continue Reading

acalabrutinib (01-17-2018)

Generic Name: acalabrutinib Trade Name: CALQUENCE® For which conditions is this drug approved? CALQUENCE is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. What is the mechanism of action? CALQUENCE... Continue Reading

CALQUENCE® (01-17-2018)

Generic Name: acalabrutinib Trade Name: CALQUENCE® For which conditions is this drug approved? CALQUENCE is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. What is the mechanism of action? CALQUENCE... Continue Reading

IDHIFA® (01-17-2018)

Generic Name: enasidenib Trade Name: IDHIFA® For which conditions is this drug approved? IDHIFA is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected... Continue Reading

enasidenib (01-17-2018)

Generic Name: enasidenib Trade Name: IDHIFA® For which conditions is this drug approved? IDHIFA is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected... Continue Reading

betrixaban (01-17-2018)

Generic Name: betrixaban Trade Name: BEVYXXA® For which conditions is this drug approved? BEVYXXA is indicated for the prevention of venous thromboembolism (VTE) in adults who are hospitalized for an acute illness and are have risk factors for VTE. VTE... Continue Reading

BEVYXXA® (01-17-2018)

Generic Name: betrixaban Trade Name: BEVYXXA® For which conditions is this drug approved? BEVYXXA is indicated for the prevention of venous thromboembolism (VTE) in adults who are hospitalized for an acute illness and are have risk factors for VTE. VTE... Continue Reading

« Previous PageNext Page »